MBX Biosciences Inc. (MBX)
NASDAQ: MBXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MBX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.46B
- EPS (TTM)
- -$3.03
- Dividend yield
- None
- 52-week range
- 26.14 – 72.64
- Day range
- 49.36 – 54.43
- Volume / Avg
- 581.89K / 532.80K
- Beta
- —
- Shares outstanding
- 49.66M
52-week range
MBX stock today
MBX Biosciences (MBX) closed at $49.55 on Nov 20, down 7.23% (-$3.86), versus the S&P 500's 3.70% decline. Shares are 31.8% below their 52-week high of $72.64, set on Aug 5, 2026 and 89.6% above the 52-week low of $26.14, in the middle of the past year's range. MBX is up 57.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 83.0%.
MBX Biosciences has posted a net loss over the last twelve months (EPS of -$3.03), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About MBX Biosciences
Company profileMBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Steven L. Hoerter
- Headquarters
- Carmel, IN
- Employees
- 63
- IPO year
- 2024
- Website
- mbxbio.com
Financial highlights
Full financialsMBX Biosciences reported a net loss of $87.0 million, compared with a loss of $61.9 million a year earlier. Diluted earnings per share came in at -$2.38.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Growth | — | — | — |
| Net income | $-87.00M | $-61.92M | $-32.56M |
| EPS (diluted) | $-2.38 | $-5.82 | $-31.96 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$95.09+91.91%
- Strong buy 3
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-1.29 vs $-0.80
- Surprise
- -61.25%
MBX news
All MBX newsMBX Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IDYAIDEAYA Biosciences Inc. | 25.56 | -2.33% | $2.47B | vs MBX |
| XNCRXencor Inc. | 33.26 | -2.21% | $2.50B | vs MBX |
| PBHPrestige Consumer Healthcare Inc. | 49.63 | +0.06% | $2.35B | vs MBX |
| HCMHUTCHMED (China) Limited ADR | 13.22 | -1.71% | $2.30B | vs MBX |
| ZLABZai Lab Limited ADR | 21.03 | -4.06% | $2.63B | vs MBX |
| RCUSArcus Biosciences Inc. | 15.62 | -1.01% | $2.25B | vs MBX |
| PHVSPharvaris N.V. | 31.28 | -1.20% | $2.21B | vs MBX |
| PRGOPerrigo Company plc | 15.94 | -0.62% | $2.21B | vs MBX |
Indexes, lists and sector
MBX Biosciences stock FAQ
What is MBX Biosciences's stock price today?
MBX last traded at $49.55 as of Nov 20, 4:00 PM EST, down 7.23% on the day. Prices are delayed at least 15 minutes.
Who is MBX Biosciences's CEO?
Mr. Steven L. Hoerter is the chief executive officer of MBX Biosciences Inc., which has about 63 employees.
What is the MBX 52-week high?
The 52-week high for MBX is $72.64 and the 52-week low is $26.14. The stock is currently 31.8% below its high.